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Alzheimer's diseaseγ-Secretase is a fascinating, multi-subunit, intramembrane cleaving protease that is now being considered as
a therapeutic target for a number of diseases. Potent, orally bioavailable γ-secretase inhibitors (GSIs) have
been developed and tested in humans with Alzheimer's disease (AD) and cancer. Preclinical studies also
suggest the therapeutic potential for GSIs in other disease conditions. However, due to inherent mechanism
based-toxicity of non-selective inhibition of γ-secretase, clinical development of GSIs will require empirical
testing with careful evaluation of beneﬁt versus risk. In addition to GSIs, compounds referred to as γ-secretase
modulators (GSMs) remain in development as AD therapeutics. GSMs do not inhibit γ-secretase, but modulate
γ-secretase processivity and thereby shift the proﬁle of the secreted amyloidβ peptides (Aβ) peptides produced.
AlthoughGSMs are thought to have an inherently safemechanismof action, their effects on substrates other than
the amyloidβ protein precursor (APP) have not been extensively investigated. Herein,wewill review the current
state of development of GSIs and GSMs and explore pertinent biological and pharmacological questions
pertaining to the use of these agents for select indications. This article is part of a Special Issue entitled:
Intramembrane Proteases.
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In concert with three other proteins, APH1, PEN2, and Nicastrin,
presenilin 1 (PSEN1) or 2 (PSEN2) function as the catalytic core of
the intramembrane cleaving protease called γ-secretase [1–3]. This
multi-subunit protease cleaves within the transmembrane domains
(TMDs) of over 100 type 1 membrane proteins [4]. γ-Secretase wasembrane Proteases.
l rights reserved.originally identiﬁed as the protease responsible for the generation of
Aβ, and thus considered a prime therapeutic target in Alzheimer's dis-
ease (AD) [5,6]. However, it was soon recognized that γ-secretase cata-
lyzed cleavages regulate a variety of signaling events by untethering the
cytoplasmic domain of various transmembrane proteins from themem-
brane, allowing these domains to transduce signals to the nucleus [7,8].
It is now clear that regulated intramembrane proteolysis carried out by
γ-secretase is another means for cells to transmit and regulate signals
across a lipid bilayer, though in other cases γ-secretase may also play
a role in transmembrane protein turnover [9,10].
γ-Secretase is an unusual protease. It is highly promiscuous in terms
of the transmembrane domain (TMD) sequences it cleaves. Although not
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shedding and co-localization of γ-secretase with the resulting mem-
brane stub in subcellular compartments [11,12]. Studies of amyloid β
protein precursor (APP) and Notch 1 indicate that γ-secretase initially
cleaves the TMD of a protein at a site near the cytoplasmic face of the
membrane [8,13–15]. In APP this initial cleavage is then followed by
3–5 sequential di, tri, or tetrapeptide cleavages [14]. Thus, γ-secretase
cleavage of transmembrane protein results in two potentially biological-
ly active fragments: the cytoplasmic intracellular domain and a small se-
creted peptide. Fig. 1 illustrates the typical processing of a generic type 1
membrane protein by γ-secretase. For most substrates, the initial
γ-secretase cleavage site and the extent of processivity have not been
deﬁned.
Primarily because γ-secretasewas a therapeutic target in AD, a pleth-
ora of γ-secretase inhibitors (GSIs) have been developed that effectively
inhibit γ-secretase cleavage in humans [16]. Indeed, “druggability” of
γ-secretase has not been an issue even when the identity of the target
was unknown in these blind screens. γ-Secretase is a highly tractable
therapeutic target and numerous orally-bioavailable, brain penetrant
GSIs have been developed [16,17] (see Fig. 2 for examples). Many of
these GSIs are highly potent and show excellent bioavailability and
pharmacokinetic properties. In AD the efﬁcacy of GSIs has been tied to in-
hibition of amyloid β protein (Aβ); thus, in AD, GSIs have been concep-
tualized as “Aβ production inhibitors” [16]. GSIs can decrease Aβ
production in human and mouse brain and chronic administration de-
creases Aβ deposition in amyloid β protein precursor (APP) mouse
models [18–21]. These GSIs have been important tools in the AD ﬁeld,
but also have served as essential elements of preclinical proof of concept
studies for many different disease indications. In addition to GSIs, com-
pounds referred to as γ-secretase modulators (GSMs) that modulate
processivity of γ-secretase have been identiﬁed and remain in develop-
ment as potentially inherently safeways to selectively target Aβ42 in AD.
Herein, we will review the development status of both GSIs and
GSMs. For GSIs we will largely focus on the efforts to i) repurpose
these compounds for indications other than AD ii) design substrateFig. 1. Amodel of stepwise γ-secretase cleavage. Typical processing of a type 1 transmem-
brane protein (A), by a “sheddase” followed by sequential γ-secretase cleavages results
in release ofmultiple potentially bioactive protein fragments: the ectodomain (B), a trans-
membrane carboxyl terminal fragment (CTF) or stub (C), the cytoplasmic domain (D) and
an Aβ/p3 like domain (E). Thus, γ-secretase generates potentially bioactive fragments
(D) by an initial cleavage and (E) by processive step-wise cleavages. GSIs inhibit
the initial cleavage and GSMs alter processivity.selective GSIs. For GSMs we will discuss the current development
status and open questions regarding potential utility in AD.
2. GSIs
In the mid to late 1990s, cell-based drug screens conducted bymul-
tiple groups searching for inhibitors of Aβ production identiﬁed a
number of compounds that dramatically inhibited Aβ secretion and in-
creased levels of APP carboxyl terminal fragments (CTFs) produced by
prior α- or β-secretase catalyzed ectodomain shedding [22–29]. At the
time the ﬁrst compounds with these effects on APP processing were
identiﬁed, the protease targeted was unknown, but the cleavage activity
was referred to as γ-secretase. Thus, compounds with this proﬁle were
named GSIs. Because γ-secretase cleaved APPwithin its transmembrane
domain and generatedmultiple Aβ peptides, there weremany hypothe-
ses regarding the nature of the activity and the proteases responsible
[30,31]. Furthermore, at that time, there was general resistance to the
concept that a protease could cleave peptide bonds normally present
within the transmembrane domain (TMD) of a protein, fueling further
speculation regarding the nature of the protease responsible. Several in-
hibitor studies also demonstrated that γ-secretase possessed multiple
pharmacologically dissociable cleavage activities indicating that it may
be more than one protease [32,33]. However, genetic, GSI binding, bio-
chemical and mutational analyses soon demonstrated that γ-secretase
was a multi-protein complex with the PSEN1 or PSEN2 acting as the cat-
alytic core, and three accessory proteins, APH1, PEN2, and Nicastrin,
needed for complex assembly and stability in cells [1–3,34]. Although it
remains formally possible that small-molecules that inhibit γ-secretase
cleavage could bind one of the other subunits, GSI binding studies sug-
gest that the target of most GSIs is PSEN1 and 2.
PSEN1 and 2 are now known to be part of a larger family of
intramembrane cleaving aspartyl proteases which include ﬁve human
homologs referred to as signal peptide peptidases (SPP (HM123),
SPPL3, SPPL2a,b,c) [35–37]. SPPs differ from PSENs in that they cleave
the transmembrane domain of type 2 as opposed to type 1 membrane
proteins, and at least for SPP (HM13), the apparent lack of requirement
for co-factors for activity [35,38,39]. The differential cleavage speciﬁcity
appears to be determined by the opposite orientation of the two cat-
alytic aspartate residues between SPPs and PSEN family members. Of
note, the recent crystal structure of an SPP fromarchaeonMethanoculleus
marisnigri JR1 was established [40]. This structure showed that the cata-
lytic aspartates residues that reside within opposing transmembrane
domains are in close proximity to each other and the lipid membrane
surface.
Some, but not all, GSIs inhibit signal peptide peptidases as well,
though this has not been systemically studied [36,41]. When consider-
ing biological activities of various GSIs this is an important and
understudied caveat that could inﬂuence both biological response as
well as potential toxicities. Indeed, it has been reported that SPP, and
not PSEN1 or PSEN2, is the major binding target of a GSI in some cells,
which likely reﬂects the fact that in most cells SPP is much more abun-
dant then PSEN/γ-secretase [42]. Although largely outside the scope of
this current review, SPP family members have been proposed to be po-
tential therapeutic targets in malaria, various viral infections, and more
recently in B-cell related disease [43–50]. Thus, GSIs which target SPPs
can be useful probes to examine the biological consequences of SPP
inhibition.
As noted above GSIs were initially developed as “Aβ inhibitors”. As
accumulation of Aβ aggregates in the brain is proposed to trigger AD,
and Aβ aggregate formation is a concentration dependent phenome-
non, the rationale for GSI development was strong [51]. However,
there are concerns that Aβ inhibitors have to be given for a prolonged
period of time, may work only as prophylactic therapies or in the
protracted, asymptomatic, prodromal phase where Aβ accumulates,
and will be increasingly ineffective as Aβ loads increase in the brain
[52]. Indeed, this assertion is supported by several in vivo preclinical
Fig. 2. Examples of GSIs. Begacestat, BMS-708163 and ELN-475516 have been reported to be Notch-sparing GSIs.
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more effective in a prevention paradigm [21,53,54]. To date, the clinical
experience in humans with AD is that long-term GSI treatment designed
to producemoderate levels of inhibition of γ-secretase is associatedwith
unacceptable side-effects and lack of clinical efﬁcacy [55–58]. Thus, un-
less there is an unanticipated breakthrough, γ-secretase inhibition is
not likely to be a viable chronic treatment strategy for AD. Furthermore
because of these safety issues, it is almost certain that GSIs will not be
suitable for testing in asymptomatic individuals at risk for AD.
Outside of the CNS, therapeutic inhibition of γ-secretase has been
most often associated with reduced Notch 1 signaling; GSIs are often
thought of in these settings as “Notch 1 inhibitors” [59–62]. γ-Secretase
has now been proposed to be a therapeutic target in various cancers
[59,61,63–81], immunologic disorders including graft versus host disease
[82,83], vasculitis [84], macular degeneration [85], diabetic nephropathy
[86,87], ischemic reperfusion injury in the kidney [88], ischemic stroke
[89], traumatic brain injury, [90], hearing loss [91] and ﬁbrosis [92]. It is
also likely that additional disease indications may emerge. Currently, a
main focus of the repurposing of γ-secretase inhibitors (GSIs) has been
in cancer with multiple human trials underway (Table 1). Both GSI
monotherapy and combination therapies with other agents are being
explored.
The development of GSIs formost cancers aswell as other indications
has been primarily based on the premise that GSIs act by inhibiting the
cleavage of Notch 1, as inhibition of γ-secretase cleavage blocks Notch
1 signaling [59,78,93,94]. Although studies in T-cell lymphoblastic leuke-
mia (T-ALL) unequivocally demonstrate that Notch 1 plays a central role
in T-ALL tumor development [79]; the role of Notch 1 signaling has not
been as critically examined in most solid tumors. Notch 1 signaling has
a normal function in maintenance, development and cell fate. It also
has been shown to promote cell survival, angiogenesis and treatment
resistance in numerous cancers, both through direct Notch 1 signalingTable 1
GSIs in trial for Cancer.
Indication GSI Single agent Combination
Breast cancer RO4929097[193,194]
MK0752[123]
Yes Yes
Glioma/GBM RO4929097 Yes Yes
Pancreatic cancer RO4929097 Yes Yes
Lung cancer RO4929097 Yes Yes
Melanoma RO4929097 Yes Yes
Leukemia/lymphoma RO4929097
MK0752
PF-03084014 [64,81]
Yes Yes
Ovarian cancer RO4929097 Yes Yes
Kidney cancer RO4929097 No Yes
Colorectal cancer RO4929097 No Yes
Sarcomas RO4929097 No Yes
Endometrial cancer RO4929097 No Yes
Prostate cancer RO4929097 No Yesand crosstalk with other key oncogenic pathways [94–99]. However, a
comprehensive examination of themechanismof action ofGSIs in cancer
and other indications, as well as their effects on angiogenesis and immu-
nity in immunocompetent models has not been conducted [59,100].
Thus, if GSIs show efﬁcacy for cancer other indications, it may be because
they synergistically altermultiple signaling pathways. It is also important
to consider the ﬁndings that GSI based inhibition of Notch 1 and perhaps
other substrates ofγ-secretase, can actually promote oncogenic transfor-
mation in certain tissues such as the skin [61]. Thus, even if acute toxic-
ities can be managed, there are concerns that GSI like many anti-cancer
therapies could promote other cancers.
With rare exceptions, the biological role of γ-secretase cleavage
of substrates other than Notch 1 has been ignored during proof of
concept preclinical repurposing studies. For example, in the GSI AD
trial, many individuals noted changes in hair color, apparently due
to inhibition of tyrosinase, another γ-secretase substrate [101]. In a
few studies other Notch paralogs and VEGFR1 have been considered
to be targets [70,102,103]. Given that tools are not readily available
to perform facile, detailed studies on the impact of γ-secretase cleav-
age on γ-secretase substrates other than APP and Notch 1; it will be
important to develop these tools to better understand the biological
consequences of GSI based therapies [4]. Indeed, the biology of
γ-secretase is complex and our understanding of it suffers from the
lamplight effect. As a ﬁeld we have largely focused only on what we
can easily see — cleavage of Notch 1 and APP [104].
Sub-unit composition and subcellular localization of γ-secretase
within the target cell may inﬂuence both activity on a given substrate
and response to a given GSI. Zhao and colleagues have shown that sul-
fonamide based GSIs selectively inhibit PSEN1 over PSEN2, whereas the
GSIs DAPT and L685458 showed minimal selectivity [105]. Similarly, re-
cent data suggest that the GSI MRK-560 preferentially targets PSEN1
over PSEN2 and that this selectivity, at least in mice, increases the toler-
ability of this GSI [106]. De Strooper and colleagues also show that het-
erogeneity with respect to the Aph1 subunit is important with respect
to viability and overall phenotype of mice, indicating that selective
targeting of Aph1b γ-secretase complexes may be less toxic [107]; how-
ever, it is not clear whether selective targeting of Aph1b γ-secretase
complexes is feasible. Other studies also provide some evidence that var-
ious γ-secretase complexes may have differential sensitivity to GSI and
different substrate preferences [108–110]. In many cases it is not clear
if substrate preference, differential spatiotemporal expression patterns
of the various γ-secretase subunits, or a combination of these factors,
contributes to the phenotype. Outside of AD, the fact that γ-secretase is
a heterogeneous activity has largely been ignored.
3. Avoiding GSI toxicity, substrate selective GSIs and other strategies
Given the toxicities associated with inhibition of Notch 1, especially
those associated with altered proliferation and maturation of gut epi-
thelium, there has been considerable effort to develop APP selective
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ciently to enable signiﬁcant reduction of Aβ production in the brain
[111]. Unfortunately, so called “Notch-sparing” APP selective GSIs that
can be shown to preferentially inhibit γ-secretase APP relative to Notch
1 in preclinical studies have not shown reduced toxicity nor increased
Aβ lowering in humans [112–119]. Furthermore, recent studies suggest
that one potential issue is that substrate selectivity has not always
been assessed in matched assays, and when GSIs inhibitory proﬁles are
examined in matched assays substrate selectivity is absent [117,120].
Thus, it is possible that the apparent substrate selectivity is really attrib-
utable to different in vitro assays. Discrepant IC50 valuesmay arise when
using reporter assays forγ-secretase activity that rely on translocation of
endogenous or transcription factor tagged intracellular domains of a
given substrate. In these assays, γ-secretase cleavage liberates the intra-
cellular domain and enables it to translocate to the nucleus where it ac-
tivates a reporter gene [121,122]. It is not clear that these reporter assays
accurately reﬂect effects on cleavage, as there are often large differnces
between inhibitor IC50s in the reporter assays versus direct cleavage as-
says. One thought is that the overexpression of and cleavage of substrate
may over-saturate the transcriptional reporter; thus; signiﬁcant inhibi-
tion of cleavage can be observed before the reporter activity is decreased.
Based on the collective experience to date, it is likely that a much
more comprehensive assessment of GSI selectivity for inhibition of mul-
tiple substrates, aswell as biomarkers to track inhibition of non-APP sub-
strates in vivo will be needed to support future efforts to develop
substrate selective GSIs. Similarly, development of GSIs designed to tar-
get a speciﬁc γ-secretase complex will be facilitated by development of
such biomarkers that can facilely track inhibition of multiple substrates.
Themost likely biomarker candidates are the Aβ-like peptides produced
by γ-secretase cleavage, as these are likely to be present in body ﬂuids
and detectable using sandwich ELISAs or mass-spectrometry. Alterna-
tively one might collect peripheral blood and examine the accumulation
of substrate derived carboxyl terminal fragments in peripheral leuko-
cytes, but this will likely limit the number of substrates that could be
assayed. Until such assays are available we will not know whether we
can predict with any accuracy the differential in vivo activity of a given
GSI using current preclinical models.
With the repurposing of GSIs for cancer, one of the key ﬁndings
from the early human trials is that subacute dosing with GSIs is rea-
sonably well-tolerated especially when dosing regimens are altered
so that dosing is not continuous but intermittent [123]. Alternatively,
administration of glucocortocoids with GSI dramatically attenuated
gastrointestinal toxicity [124]. In this regard, development of addi-
tional tools that better enable assessment of GSI activity on multiple
substrates may help to optimize individual dosing so that maximal
clinical beneﬁt is achieved while minimizing side-effects. Of course
in cancer as opposed to AD, there is generally a willingness to accept
some level of toxicity if there are any signs of efﬁcacy.
One important question that remains is whether all current GSIs are
biologically equivalent. ThoughmanyGSIs currently being used for can-
cer trials are considered “pan-GSI inhibitors” this labelingmay be amis-
nomer. GSI inhibitory activity is often only established for Aβ and Notch
1 [16]. The net action of GSIs may be inﬂuenced by multiple factors
within a target cell [9,107,109,125,126]. These factors not only include
the variable subunit composition of the γ-secretase complexes but
also a) the expression of the substrate in the target cell, b) the location
of the substrate, c) sheddase expression, and d) activation of the
sheddase. Thus, GSI action could be unexpectedly inﬂuenced by any of
these factors. Clearly, given the investment in repurposing GSIs, addi-
tional studies directly comparing biological actions of various GSI used
in clinical trials in various model systems are warranted.
γ-Secretase cleavage is remarkably promiscuous, but somehow regu-
lated [9]. To our knowledge there is no type 1 membrane protein which
has been shown to be processed by a sheddase in which the membrane
stub is not subsequently processed by γ-secretase. Furthermore, muta-
tional studies and comparison of the TMD sequences cut by γ-secretasereveal that there is little sequence speciﬁcity to γ-cleavage [32,127–].
Clearly, ligand binding induced ectodomain shedding is one regulatory
step in γ-cleavage, but for many constitutively shed and processed pro-
teins there must be other ways of regulating signaling [131]. Previously,
we and others have shown that γ-secretase cleavage of APP was located
in cholesterol rich buoyant membranes (lipid rafts) and that cholesterol
depletion blocked cleavage [12,132–134]. Subsequently, a number of
labs have conﬁrmed theseﬁndings for APP, and recently thiswas extend-
ed to show that γ-secretase interacts with tetraspanins and this interac-
tion facilitates γ-secretase localization in raft domains [135,136].
Another study suggested that Notch 1 γ-secretase cleavage occurs on
the cell surface whereas APP occurs in intracellular compartments
[131]. These data indicated that co-localization of ectodomain-shed
substrate CTF and γ-secretase, helped to regulate cleavage. In contrast
during development, γ-secretase appears to be active in both raft and
non-raft membranes. How the potential altered localization of γ-
secretase inﬂuences activity and response to a GSI is not known, but
again an area worthy of further study.
4. GSMs
γ-Secretase cleavage of APP generates a number of Aβ peptides
[32,137]. In most cells Aβ1–37, 38, 39, and 42 are produced at low levels
(typically each represents 5–20% of total Aβ detected) and the major
species generated is Aβ1–40 (typically over 50% of total Aβ). Other Aβ
peptides can also be variably detected at low levels including Aβ1–34,
1–36, 1–41 and 1–43. Shifts in the relative production of these various
Aβ peptides towards Aβ1–42, is tightly associated with risk for AD
[138,139]. Mutations in APP and PSEN1/2 that elevate the relative level
of Aβ42 by even as little as 30% deterministically cause early onset AD
[140], and it now appears that the deposition process likely begins
20 years before the onset of dementia in these individuals [141]. Seminal
biochemical studies show that Aβ1–42 aggregates into amyloid ﬁbrils
and other assemblies much more readily than Aβ1–40 [142,143], and
transgenic modeling studies show that AD-associated APP and PSENmu-
tations increases Aβ42 levels and accelerate Aβ deposition [144,145]. In
addition other studies using various fusion protein strategies to express
Aβ1–42 and Aβ1–40 in the absence of APP overexpression show that
Aβ42 is required to drive Aβ deposition, and that Aβ1–40 may actually
inhibit Aβ deposition [146–149].
Some early studies of peptidic GSIs showed that although they
reduced total Aβ levels and increased APP CTF; they also shifted the
proﬁle of Aβ species produced, in some cases increasing the absolute
level of longer Aβ1–41,42, and 43 [30,32,33]. As discussed earlier
these data fueled some speculation that multiple proteases contrib-
uted to the generation of the various Aβ peptides. Subsequently,
we identiﬁed a subset of non-steroidal anti-inﬂammatory agents
(NSAIDs) such as ibuprofen, sulindac and indomethacin, as prototypic
agents capable of lowering Aβ42 selectively in vitro and in vivo by
targeting the γ-secretase complex [150–152]. The classic signature
of these ﬁrst generation GSMs differed from previous GSIs in that
they did not alter total Aβ production, or increase APP CTFs and no al-
terations in the generation of several other γ-secretase substrates, but
instead decreased Aβ1–42 levels and increased Aβ1–38 [152]. These
data suggested that it may be possible to use GSMs as therapeutic
agents for AD as they would selectively target the longer more path-
ogenic forms of Aβ. In addition to these classic GSMs, other com-
pounds referred to as inverse GSMs (iGSMs) were also identiﬁed
[153,154]. These compounds were often structurally related to the
GSMs but typically lacked an acidic group, and increased, rather
than lowering, Aβ1–42. In some, but not all cases, these compounds
also decreased levels of shorter Aβ peptides including (Aβ1–37, 38,
39). Since the initial identiﬁcation of NSAID-based GSMs there has
been a major effort to improve potency, pharmacokinetic properties
and ﬁnd new non-acidic classes of GSMs. This has led to the identiﬁ-
cation of a number of acidic GMSs with dramatic increases in potency
Fig. 3. Examples of GSMs. Indomethacin is an NSAID GSM, GSM-1 is an example of a potent 2nd generation acidic GSM and E2012 is an example of a non-acidic GSM.
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scaffold that are also much more potent than the ﬁrst generation
NSAID-based GSMs (Fig. 3) [155–172]. More recently triterpenoid
natural product derived GSMs have been identiﬁed [173,174]. Overall
there are subtle differences between these GSMs that may be thera-
peutically important. While the more potent acidic GSMs show the
classic GSM signature of lowering Aβ1–42 and increasing Aβ1–38
[175], non-acidic GSMs increase Aβ1–37 and 1–38 and lower both
Aβ1–40 and 1–42 [171]. In contrast, the triterpenoid GSM appears
to be even more distinct lowering both Aβ1–38 and 1–42 [173,174].
These differential properties and comparison to GSIs are described
in Table 2.
Until recently the mechanism of how GSMs shifted γ-secretase
cleavage was poorly understood. Today, building on the sequential
cleavage model developed by Ihara and colleagues [14], there is evi-
dence that GSMs act as processivity enhancers, and iGSMs as inhibitors
of processivity [120]. At least for APP and Notch, neither acidic,
non-acidic GSMs nor iGSMS signiﬁcantly alter the initial γ-secretase
cleavage site [150,152,176,177], but they do appear to primarily alter
the subsequent number of processivity cleavage events. For classic
GSMs this means that they increase cleavage of Aβ1–42 to Aβ1–38;
for many iGSMs, they appear to do the opposite. Although not directly
established non-acidic GSMs appear would be proposed to increase
processivity of Aβ1–40 and Aβ1–42 to Aβ1–37 and Aβ1–38. The novel
triterpenoid GSMs recently described by Satori Pharmaceuticals,
are somewhat unusual as they decrease both Aβ1–38 and Aβ1–42
[173,174]. How this unusual type of modulation occurs is unclear,
but could be accounted for either by effect on the substrate product
line that is determined by the initial γ-secretase cleavage (i.e. a shift
to cleavage that initially generates Aβ1–49) or decreased processivity
along the Aβ1–42 product line. If the latter is the case, then an even
longer Aβ peptide should accumulate.
Notably, for the more well studied GSMs there is clear evidence
that these compounds do not alter Notch 1 processing to any great
extent [129,150,152]. They preserve Notch 1 signaling and thus are
thought to be inherently safe. Although it is almost certain that GSMs
will to varying extents modulate cleavage of some other
γ-secretase substrates, there is no evidence to date that this will
have signiﬁcant biological impact. GSMs are not likely to alter signal-
ing events mediated by the initial γ-cleavage and subtle shifts in the
length of the short Aβ like fragments produced by subsequent
γ-cleavages are unlikely to have signiﬁcant liabilities.Table 2
Comparison of effects of GSIs, GSMs and iGSMs.
Total Aβ Aβ1–37 Aβ1–38 Aβ1–40
GSI ↓ ↓ ↓ ↓
NSAID-GSM = = ↑ =
2nd generation acidic GSMs = = ↑ =
Non-acidic = ↑ ↑ =
Triterpenoid = = ↓ =
iGSM = ↓ or = ↓ or = =
a These EC50s are approximations of the most potent compounds reported.There remains some controversy over the binding site of GSMs.
Low potency NSAID-based GSMs have been shown to bind substrate
[171,178,179], whereas more potent acidic GSMs and non-acidic
GSMs have been shown to bind PSEN1 or PEN-2 [171,180–182]. The
target of the triterpenoid natural product has not been established.
Notably, there is evidence that the effect of GSMs is substrate selective
and that sequenceswithin substrate dramatically inﬂuence processivity
of γ-secretase [129,130]. Collectively these binding studies and sub-
strate selective effects of GSMs suggest that there may tripartite inter-
actions between GSM, γ-secretase and substrate that subtly alter
processivity perhaps by altering residence time of the substrate within
the active site of γ-secretase. Another area of some controversy is
whether APP and PS1mutations inﬂuence the potency of GSMs. Though
potency of 1st generation GSM were reported to be altered by AD-
linked PS1 and APP mutations, other studies with more potent GSMs
showed little effect on potency [175,183].
5. Clinical development of GSMs
APhase III study of theNSIADbasedGSMTarenﬂurbil (R-ﬂurbiprofen)
in patients with mild AD showed no beneﬁt on cognitive or functional
outcomes [184]. Tarenﬂurbil is aweakGSMwith lowCNSpenetrance lim-
iting general inferences based on this trial with respect to clinical efﬁcacy
of more potent, CNS penetrant GSMs [11,151,160,185]. Many companies
and academic groups have ongoingGSMdevelopment programs and sev-
eral more potent GSM have entered early phase clinical trials. TheGSM,
CHF5074, based on R-ﬂurbiprofen developed by Chiesi Pharmaceuticals
has advanced the furthest in human testing completing a phase II trial
[157]. Recent data suggest that while this compound may possess GSM
activity it may have a rich pharmacology andmay have additional mech-
anism(s) of action besides altering Aβ42 [186–188]. One clear challenge
in the development of potent GSMs that have been recently reviewed
[160], is the balance between liophillicity and potency. Although potency
and brain penetration have been dramatically improved in 2nd and 3rd
generation GSMs, this has been associated with increases in lipophillicty
of the compounds. It has been proposed that this lipophillicity as well as
potential glucuronidation of acidic GSMs contributes to what are thought
to be off-target, primarily liver toxicities [160].
Aswith theGSIs, there are againmajor concerns that GSM therapy in
patients with symptomatic AD is almost certain to fail, unless the com-
pound has additional mechanism of action not linked to Aβ that prove
to beneﬁcial [52]. Although Aβ1–42 or other longer Aβ peptides areAβ1–42 APP CTF Notch EC50↓ Aβ42a Binding target
↓ ↑ ↓ ~500 pM PSEN1/2
↓ = = ~10 μM APP/Substrate
↓ = = ~50 nM PSEN
↓ = = ~50 nM PSEN/PEN2
↓ = = ~50 nM ?
↑ = = ~10 μM APP/substrate
2903T.E. Golde et al. / Biochimica et Biophysica Acta 1828 (2013) 2898–2907critical for initiating Aβ deposition, shorter Aβ accumulate in the AD
brain [189]. Thus, shifting Aβ cleavage after nucleation events have
occurred is not likely to dramatically alter Aβ deposition kinetics.
Thus, a major challenge is whether a sufﬁciently safe GSM can be devel-
oped that can potentially be used as a prophylactic agent in asymptom-
atic individuals. A ﬁnal issue of clinical relevance relates to the biology
of the shorter Aβ peptides. There has been little systematic investigation
of these peptides. Although one report suggested that Aβ1–38 may
behave in vitro like Aβ1–42, this important ﬁnding has not been
reproduced [190]. Further study of these short peptides may reveal
unique properties that might help to guide development of GSMs. For
example Aβ1–40 appears to act an inhibitor of Aβ1–42 nucleation and
aggregation in vivo [191,192], but whether Aβ1–37 or 1–38 inhibit ag-
gregation in vivo is unknown. Given that non-acidic GSMs decrease
Aβ1–40 whereas acidic GSMs do not, the distinct action of these two
classes of GSMs could have major impact on efﬁcacy.
6. Conclusions
From a biological perspective γ-secretase is both a fascinating and
complex enzyme that is increasingly being scrutinized as a therapeutic
target for conditions other than AD. There are many gaps in our knowl-
edge that need to be answered to optimally move forward with devel-
opment of GSIs for cancer and other indications and the continued
development of GSMs for AD. Future studies addressing the contribu-
tion of other substrates to effects of GSIs and even GSMs, and efforts
to determine if all GSI are biologic equivalents certainly will be key
steps in these development efforts.
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